Final Phase 2 Study Results of Acalabrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
Research Summary: Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is a low-grade B-cell malignancy. Since
Research Summary: Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is a low-grade B-cell malignancy. Since
Research Summary: Traditionally, the gold standard treatment option for patients with cisplatin-eligible clinically localized muscle
Research Summary: For patients with bacillus Calmette-Guérin (BCG)–naïve, high-risk non-muscle invasive bladder cancer (NMIBC), the
Research Summary: Many estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) breast tumors
Learn how cilta-cel improved survival, disease control, and symptom outcomes versus standard care in lenalidomide-refractory multiple myeloma.
Explore how adding durvalumab to chemotherapy may improve survival and offer a cost-effective treatment option for muscle invasive bladder cancer.
Learn how consolidation durvalumab after sequential chemoradiotherapy demonstrated favorable long-term survival and a manageable safety profile in unresectable stage III NSCLC in the PACIFIC-6 trial.
Research Summary: KRAS G12C mutations occur in a substantial subset of advanced non-small cell lung
Research Summary: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are B-cell malignancies that
Learn how capivasertib plus fulvestrant works in advanced breast cancer, including its effectiveness, safety, and why this dosing approach may help improve treatment outcomes.
Learn how acalabrutinib compares to other CLL treatments, with insights on cardiac safety, atrial fibrillation risk, and what recent trials reveal about treatment options.
Learn how experts recommend using 31-GEP testing to improve melanoma risk assessment, guide sentinel lymph node biopsy decisions, and personalize care.
Learn how the 31-gene expression profile test helps predict recurrence, metastasis, and survival in cutaneous melanoma to support personalized risk assessment.
Explore preclinical findings showing imlunestrant overcomes ESR1-mutant resistance and suppresses tumor growth in ER-positive breast cancer.
Learn how ciltacabtagene autoleucel compared with standard treatments for relapsed/refractory multiple myeloma in this matching-adjusted indirect comparison.
Research Summary: The EMBER-3 trial1 was a Phase III, open-label study that evaluated imlunestrant, a
Research Summary: For patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM), prior reports have shown
Research Summary Chimeric antigen receptor T-cell (CAR-T) therapy is typically administered in the inpatient setting,
Research Summary This study1 evaluated the Medicare cost impact of choosing among covalent Bruton tyrosine
See how osimertinib before surgery may improve outcomes for patients with resectable EGFR-mutated non-small cell lung cancer.
©2026 Oncology Matrix. All Rights Reserved.